Literature DB >> 3132382

Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis.

R Krausse1, U Ullmann.   

Abstract

The susceptibility of 67 isolated Ureaplasma urealyticum, 25 Mycoplasma hominis and five Mycoplasma spp. reference strains to fleroxacin, ofloxacin, josamycin and doxycycline was determined by agar dilution. Josamycin had the best activity against Ureaplasma urealyticum, followed in order by doxycycline, ofloxacin and fleroxacin. All the strains were inhibited by josamycin at 0.4 mg/l, while only 38.8% of the strains were inhibited by doxycycline at this concentration. Mycoplasma hominis strains were more susceptible to doxycycline, ofloxacin and fleroxacin than were Ureaplasma urealyticum strains. Here, doxycycline had the best activity followed by ofloxacin, josamycin and fleroxacin. Notably, three Ureaplasma urealyticum strains and one Mycoplasma hominis strain were not inhibited by 6.4 mg/l doxycycline.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132382     DOI: 10.1007/bf01962178

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  In vitro susceptibility studies with josamycin and erythromycin.

Authors:  L J Strausbaugh; J A Dilworth; J M Gwaltney; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

2.  In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

Authors:  N Manek; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors:  K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

4.  Antimycoplasmal activity of ofloxacin (DL-8280).

Authors:  Y Osada; H Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T mycoplasmas) in primary cultures of clinical material.

Authors:  M C Shepard; C D Lunceford
Journal:  J Clin Microbiol       Date:  1976-06       Impact factor: 5.948

6.  Macrolide antibiotics M-4365 produced by Micromonospora. IV. Antimycoplasmal activity of antibiotic M-4365 G2 (de-epoxy rosamicin).

Authors:  T Onta; I Maezawa; A Kinumaki; S Ohshima; T Yamaguchi
Journal:  J Antibiot (Tokyo)       Date:  1981-06       Impact factor: 2.649

7.  The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.

Authors:  G L Ridgway; G Mumtaz; F G Gabriel; J D Oriel
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 8.  Antimicrobial susceptibility and susceptibility testing of Mycoplasma hominis: a review.

Authors:  S M Bygdeman; P A Mårdh
Journal:  Sex Transm Dis       Date:  1983 Oct-Dec       Impact factor: 2.830

9.  Standardized method for determining antimicrobial susceptibility of strains of Ureaplasma urealyticum and their response to tetracycline, erythromycin, and rosaramicin.

Authors:  J A Robertson; J E Coppola; O R Heisler
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Persistence of Mycoplasma hominis after therapy: importance of tetracycline resistance and of coexisting vaginal flora.

Authors:  L A Koutsky; W E Stamm; R C Brunham; C E Stevens; B Cole; J Hale; P Davick; K K Holmes
Journal:  Sex Transm Dis       Date:  1983 Oct-Dec       Impact factor: 2.830

  10 in total
  6 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 4.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 6.  Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.

Authors:  R Janknegt; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1989-04-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.